Cargando…
SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients
BACKGROUND: Although SARS-CoV-2 vaccines have proven effective in eliciting a protective immune response in healthy individuals, their ability to induce a durable immune response in immunocompromised individuals remains poorly understood. Primary antibody deficiency (PAD) syndromes are among the mos...
Autores principales: | Lin, Frank J., Doss, Alexa Michelle Altman, Davis-Adams, Hannah G., Adams, Lucas J., Hanson, Christopher H., VanBlargan, Laura A., Liang, Chieh-Yu, Chen, Rita E., Monroy, Jennifer Marie, Wedner, H. James, Kulczycki, Anthony, Mantia, Tarisa L., O’Shaughnessy, Caitlin C., Raju, Saravanan, Zhao, Fang R., Rizzi, Elise, Rigell, Christopher J., Dy, Tiffany Biason, Kau, Andrew L., Ren, Zhen, Turner, Jackson S., O’Halloran, Jane A., Presti, Rachel M., Fremont, Daved H., Kendall, Peggy L., Ellebedy, Ali H., Mudd, Philip A., Diamond, Michael S., Zimmerman, Ofer, Laidlaw, Brian J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817149/ https://www.ncbi.nlm.nih.gov/pubmed/36618402 http://dx.doi.org/10.3389/fimmu.2022.1033770 |
Ejemplares similares
-
mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes
por: Zimmerman, Ofer, et al.
Publicado: (2022) -
Patients With Primary Antibody Deficiency Syndromes Show Attenuated Neutralizing Activity of SARS-CoV-2 Following COVID-19 Vaccination
por: Doss, Alexa, et al.
Publicado: (2022) -
Immunoglobulin replacement products in current clinical use in the United States have poor neutralizing activity against SARS-CoV-2 Omicron strains
por: Doss, Alexa, et al.
Publicado: (2023) -
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022) -
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura, et al.
Publicado: (2021)